206 related articles for article (PubMed ID: 27756408)
1. Prediction of chemo-response in serous ovarian cancer.
Gonzalez Bosquet J; Newtson AM; Chung RK; Thiel KW; Ginader T; Goodheart MJ; Leslie KK; Smith BJ
Mol Cancer; 2016 Oct; 15(1):66. PubMed ID: 27756408
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data.
Abdallah R; Chon HS; Bou Zgheib N; Marchion DC; Wenham RM; Lancaster JM; Gonzalez-Bosquet J
Int J Gynecol Cancer; 2015 Jul; 25(6):1000-9. PubMed ID: 26098088
[TBL] [Abstract][Full Text] [Related]
3. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
4. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
Benvenuto G; Todeschini P; Paracchini L; Calura E; Fruscio R; Romani C; Beltrame L; Martini P; Ravaggi A; Ceppi L; Sales G; Donati F; Perego P; Zanotti L; Ballabio S; Grassi T; Delle Marchette M; Tognon G; Sartori E; Adorni M; Odicino F; D'Incalci M; Bignotti E; Romualdi C; Marchini S
Int J Cancer; 2020 Jul; 147(2):565-574. PubMed ID: 32096871
[TBL] [Abstract][Full Text] [Related]
6. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
7. Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.
Zhan SJ; Liu B; Linghu H
Oncol Rep; 2018 Jun; 39(6):2653-2663. PubMed ID: 29693178
[TBL] [Abstract][Full Text] [Related]
8. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma.
Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q
Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
Hou S; Dai J
PLoS One; 2018; 13(3):e0192812. PubMed ID: 29494610
[TBL] [Abstract][Full Text] [Related]
10. Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.
Bosquet JG; Marchion DC; Chon H; Lancaster JM; Chanock S
Cancer Res; 2014 Jul; 74(14):3902-12. PubMed ID: 24848511
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
Jazaeri AA; Awtrey CS; Chandramouli GV; Chuang YE; Khan J; Sotiriou C; Aprelikova O; Yee CJ; Zorn KK; Birrer MJ; Barrett JC; Boyd J
Clin Cancer Res; 2005 Sep; 11(17):6300-10. PubMed ID: 16144934
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
13. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
Barlin JN; Jelinic P; Olvera N; Bogomolniy F; Bisogna M; Dao F; Barakat RR; Chi DS; Levine DA
Gynecol Oncol; 2013 Mar; 128(3):512-7. PubMed ID: 23168173
[TBL] [Abstract][Full Text] [Related]
14. A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
Song J; Zhang W; Wang S; Liu K; Song F; Ran L
Int J Oncol; 2018 Aug; 53(2):866-876. PubMed ID: 29749482
[TBL] [Abstract][Full Text] [Related]
15. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
16. Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Chen P; Huhtinen K; Kaipio K; Mikkonen P; Aittomäki V; Lindell R; Hynninen J; Auranen A; Grénman S; Lehtonen R; Carpén O; Hautaniemi S
Cancer Res; 2015 Aug; 75(15):2987-98. PubMed ID: 26122843
[TBL] [Abstract][Full Text] [Related]
17. A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma.
Liu LW; Zhang Q; Guo W; Qian K; Wang Q
Biomed Res Int; 2016; 2016():6945304. PubMed ID: 27478834
[TBL] [Abstract][Full Text] [Related]
18. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
19. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
